epcoritamab
abbvie,genmab
['epcore,nhl,2', 'epcore nhl-1', 'lymphoma', 'epcore,nhl,1', 'epcoritamab', 'lymsm', 'nhl']
an expansion cohort from the phase 2 epcore nhl-1 trial demonstrated strong efficacy of epcoritamab in patients with relapsed/refractory large b-cell lymphoma. #lymsm #eha2022 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.